Personalized Medicine in the Field of Inflammatory Skin Disorders

Personalized Medicine in the Field of Inflammatory Skin Disorders

0 Ungluers have Faved this Work
Skin inflammation is associated with a wide range of conditions which represent major health issues worldwide. Skin and mucosal surfaces represent the primary interface between the human body and the environment, susceptible to numerous factors whose action results in diseases produced by chemical substances, mechanical trauma, microbial agents, radiation, etc. Inflammation, a complex network of interactions between soluble molecules and cells, represents the main modality of the skin’s response to injuries. Numerous studies have revealed close links between chronic inflammation, oxidative stress, and carcinogenesis. Chronic inflammation induces the activation of various cell types and an increase in the production of reactive oxygen species, promoting the initiation of a malignant process. Identifying specific biomarkers is essential for understanding molecular mechanisms and developing therapies appropriate to the patient’s characteristics.Personalized medicine is an emerging field of medicine that has the potential to predict which therapy will be safe and efficacious for specific patients using an individual’s genetic profile to guide decisions regarding the diagnosis, treatment, as well as prevention of disease. This book gathers articles that present recent advancements in research involving the mechanisms that underlie the development of inflammatory skin disorders, skin and mucosal inflammation in general.

This book is included in DOAB.

Why read this book? Have your say.

You must be logged in to comment.

Rights Information

Are you the author or publisher of this work? If so, you can claim it as yours by registering as an rights holder.


This work has been downloaded 16 times via ebook links.
  1. 16 - pdf (CC BY) at


  • AK
  • alginate
  • androgenic alopecia
  • antioxidative stress strategies
  • atopic dermatitis
  • autoinflammatory disease
  • biomarker
  • biomarkers
  • biomaterial
  • C57 BL/6 mice
  • calumenin
  • Cannabinoids
  • carbohydrate oxidation
  • CD36
  • Clinical Trial
  • commercially available
  • comorbidities
  • corticosteroids
  • COVID-19
  • cSCC
  • cutaneous melanoma
  • cyclosporine
  • cytohesin 2
  • DNA oxidation
  • dressing
  • drug resistance
  • eczema
  • Epigenetic regulation
  • epigenetic therapy
  • estrogen
  • Evidence-based medicine
  • Fibers
  • gut-lung-skin barrier
  • hair density
  • halo nevi
  • hydrogel
  • IgY
  • imiquimod
  • Immune response
  • immune-mediated skin diseases
  • Immunosuppression
  • Inflammation
  • inflammatory biomarkers
  • JAK inhibitors
  • Lipid Peroxidation
  • long-chain fatty acids
  • lupus nephritis
  • medicine
  • Menopause
  • Meta-analysis
  • n/a
  • nanofibers
  • oxidized proteins
  • platelet-rich plasma
  • Prevalence
  • proteome analysis
  • psoriasis
  • psoriasis vulgaris
  • psoriatic dermatitis
  • pyoderma gangrenosum
  • Risk factors
  • S100A6
  • sea-buckthorn seed oil
  • sialidase
  • sialylation
  • sialyltransferase
  • signaling pathways
  • skin conditions and systemic inflammatory diseases
  • skin dysplastic keratinocytes
  • skin tumor
  • SR-B2
  • Sutton nevi
  • systematic review
  • systemic lupus erythematous
  • systemic sclerosis
  • target therapy
  • therapeutic targets
  • UVA
  • wound care
  • Wound healing


DOI: 10.3390/books978-3-0365-3573-9


edition cover


Copy/paste this into your site: